Onderneming Immunoprecise Antibodies Ltd Toronto S.E.
Aandelen
TQY
CA87588T2020
Farmaceutische producten
Vakgebied
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Antibody Production Project
90,4
%
| 14 | 89,6 % | 14 | 90,4 % | +1,56% |
Antibody Production Product
8,5
%
| 1 | 8,5 % | 1 | 8,5 % | -0,20% |
Cryostorage
1,2
%
| 0 | 1,8 % | 0 | 1,2 % | -36,11% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Europe
45,7
%
| 8 | 48,7 % | 7 | 45,7 % | -5,42% |
United States
45,3
%
| 5 | 35,2 % | 7 | 45,3 % | +29,67% |
Australia
3,0
%
| 1 | 8,0 % | 0 | 3,0 % | -61,39% |
Canada
3,0
%
| 0 | 3,0 % | 0 | 3,0 % | +1,96% |
Other
2,9
%
| 1 | 5,2 % | 0 | 2,9 % | -43,58% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Jennifer Bath
CEO | Chief Executive Officer | - | 21-02-18 |
Kristin Taylor
DFI | Director of Finance/CFO | - | 29-09-23 |
Ilse Roodink
CTO | Chief Tech/Sci/R&D Officer | - | 01-07-21 |
Frederick Chabot
IRC | Investor Relations Contact | - | - |
Barry Duplantis
PRN | Corporate Officer/Principal | - | - |
Kari Graber
PRN | Corporate Officer/Principal | - | - |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Mitchell Levine
CHM | Chairman | - | - |
Chris Buyse
BRD | Director/Board Member | 59 | 05-09-23 |
Jennifer Bath
CEO | Chief Executive Officer | - | 21-02-18 |
Dirk Witters
BRD | Director/Board Member | - | 05-09-23 |
Barry Springer
BRD | Director/Board Member | - | 05-09-23 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 26 315 260 | 22 738 411 ( 86,41 %) | 0 | 86,41 % |
Bedrijfsgegevens
ImmunoPrecise Antibodies Ltd.
4464 Markham Street Suite 3204
V8Z 7X8, Victoria
+250-483-0308
http://www.immunoprecise.comSector
Verkoop per activiteit
Verkoop per regio
Vaira. 1 jan. | Kapi. | |
---|---|---|
-1,26% | 89,46 mld. | |
+2,76% | 40,74 mld. | |
-9,25% | 33,03 mld. | |
+55,32% | 24,68 mld. | |
-16,48% | 15,12 mld. | |
-9,07% | 12,81 mld. | |
-12,11% | 11,79 mld. | |
-43,61% | 11,64 mld. | |
+7,79% | 8,9 mld. |